Translated complex Phase III clinical

Translated complex Phase III clinical trial data from top-tier medical literature (The New England Journal of Medicine) and US FDA Prescribing Information into an engaging, accessible Plain Language Summary (PLS) designed for patients, patient advocacy groups, and non-specialist audiences.

The summary clearly communicates complex study endpoints, such as 3-point MACE reductions, cardiovascular mortality statistics, and safety considerations, using health-literacy best practices while maintaining 100% scientific accuracy and compliance with source data.